CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery

NATerminatedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

April 19, 2018

Primary Completion Date

January 18, 2022

Study Completion Date

January 18, 2022

Conditions
Elective Cardiac Surgery
Interventions
DEVICE

CytoSorb

To evaluate the safety and performance of the CytoSorb® device to decrease the incidence or severity of acute kidney injury (AKI)

Trial Locations (20)

10032

Columbia University Medical Center, New York

10075

Northwell Health: Lennox Hill Hospital, New York

19104

University of Pennsylvania, Philadelphia

21201

University of Maryland, Baltimore

27710

Duke University Medical Center, Durham

27858

East Carolina University, Greenville

37212

Vanderbilt University, Nashville

38120

Baptist Memorial Hospital, Memphis

40202

University of Louisville, Louisville

43210

Ohio State university, Columbus

45219

The Christ Hospital Linder Research Center, Cincinnati

46202

Indiana University Health Methodist Hospital, Indianapolis

50266

Iowa Heart Center, West Des Moines

60637

University of Chicago, Chicago

73112

Integris Baptist Medical Center, Oklahoma City

77030

Baylor College of Medicine, Houston

06510

Yale School of Medicine, New Haven

04102

Maine Medical Center, Portland

02115

Brigham and Women's Hospital, Boston

07450

Valley Hospital, Ridgewood

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CytoSorbents, Inc

INDUSTRY